Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) is pleased to announce that the Company’s Board of Directors has approved the grant of 1,000,000 restricted stock units (RSUs) to William Garbarini in connection with his appointment as Chief Operating Officer, effective November 22, 2024.

The RSUs were granted under the Company’s Amended and Restated 2023 Equity Incentive Plan, will vest over a period of 24 months, and upon vesting will be settled in common shares of the Company. The RSUs and underlying common shares are ‎subject to a four ‎month and one day hold period pursuant to Canadian securities laws and the policies of the TSX Venture Exchange.

For more information please contact:‎

Mike Seckler ‎Chief Executive Officer ‎Tel: 1 (800) 760-6826 ‎Email: Info@Salonaglobal.com‎

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the ‎policies of ‎the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this ‎release.‎

Evome Medical Technologies (TSXV:EVMT)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Evome Medical Technologies 차트를 더 보려면 여기를 클릭.
Evome Medical Technologies (TSXV:EVMT)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Evome Medical Technologies 차트를 더 보려면 여기를 클릭.